Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries.
Under the terms of the agreement, Cancer Research Horizons will license Twist’s ‘Library of Libraries’, a collection of synthesised antibody libraries designed based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of antibody drug targets, for a period of five years.
Twist will receive a library access fee and will be eligible to receive annual maintenance fees as well as a share of revenue from any assets sold or transferred.
Emily Leproust, CEO and co-founder of Twist Bioscience, said: “Cancer Research Horizons acts as a conduit between academia and industry, with our collaboration enabling early-stage antibody identification through access to our ‘Library of Libraries.’ With two mission-driven organisations aligning behind innovative technology solutions to improve health to make the world a better place, the opportunity to identify new biotherapeutics offers tremendous hope to those who need it most.”
Hamish Ryder, CEO of Therapeutic Innovation at Cancer Research Horizons, commented: “We look forward to using this technology to accelerate the delivery of high-quality therapeutics and diagnostics to cancer patients, in collaboration with our academic and industrial partners.”
